From discordance to clinical decision support: integrating longitudinal imaging and ctDNA through multimodal artificial intelligence in precision oncology

Accurate treatment-response assessment increasingly requires information that is spatial, molecular, and longitudinal. Imaging depicts lesion burden, anatomical distribution, and morphological evolution, whereas circulating tumor DNA (ctDNA) provides a systemic molecular signal shaped by tumor shedding, clonal composition, assay characteristics, and treatment pressure. Because these modalities measure non-identical dimensions, disagreement between them is clinically plausible and can reflect lead-lag kinetics, site-specific progression, clonal evolution, or technical uncertainty. In this focused narrative review, we synthesize evidence for imaging-ctDNA integration and propose a multidimensional, multilabel taxonomy of discordance spanning directional, temporal, spatial, molecular, and technical dimensions. We distinguish isolated from persistent discordance and emphasize exact temporal alignment, analytical confidence, and orthogonal confirmation. Current evidence supports prognostic complementarity and demonstrates measurable discordance across tumor types, but clinical actionability is context dependent. Randomized studies such as PADA-1 show that molecular-first treatment adaptation can be beneficial when a defined biomarker is linked to a validated intervention, whereas other trials illustrate that molecular detectability alone does not guarantee benefit from early treatment. We therefore frame multimodal artificial intelligence (AI) as an uncertainty-aware decision-support approach rather than an automated treatment selector. Future systems should preserve modality-specific information, handle irregular longitudinal sampling, quantify uncertainty, identify information gaps, and recommend evidence-matched reassessment. Prospective validation should prioritize clinical utility, harms, transportability, governance, and net benefit rather than discrimination alone.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-10-27
DOI
https://doi.org/10.3389/fonc.2026.1963645
Primary Topic
Cancer Genomics and Diagnostics
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

From discordance to clinical decision support: integrating longitudinal imaging and ctDNA through multimodal artificial intelligence in precision oncology

郑健, Luyang Chi, Yong Guo
1 links
Frontiers in Oncology
Cancer Genomics and Diagnostics
article

From discordance to clinical decision support: integrating longitudinal imaging and ctDNA through multimodal artificial intelligence in precision oncology

郑健, Luyang Chi, Yong Guo
article en

Abstract

Accurate treatment-response assessment increasingly requires information that is spatial, molecular, and longitudinal. Imaging depicts lesion burden, anatomical distribution, and morphological evolution, whereas circulating tumor DNA (ctDNA) provides a systemic molecular signal shaped by tumor shedding, clonal composition, assay characteristics, and treatment pressure. Because these modalities measure non-identical dimensions, disagreement between them is clinically plausible and can reflect lead-lag kinetics, site-specific progression, clonal evolution, or technical uncertainty. In this focused narrative review, we synthesize evidence for imaging-ctDNA integration and propose a multidimensional, multilabel taxonomy of discordance spanning directional, temporal, spatial, molecular, and technical dimensions. We distinguish isolated from persistent discordance and emphasize exact temporal alignment, analytical confidence, and orthogonal confirmation. Current evidence supports prognostic complementarity and demonstrates measurable discordance across tumor types, but clinical actionability is context dependent. Randomized studies such as PADA-1 show that molecular-first treatment adaptation can be beneficial when a defined biomarker is linked to a validated intervention, whereas other trials illustrate that molecular detectability alone does not guarantee benefit from early treatment. We therefore frame multimodal artificial intelligence (AI) as an uncertainty-aware decision-support approach rather than an automated treatment selector. Future systems should preserve modality-specific information, handle irregular longitudinal sampling, quantify uncertainty, identify information gaps, and recommend evidence-matched reassessment. Prospective validation should prioritize clinical utility, harms, transportability, governance, and net benefit rather than discrimination alone.

Frontiers in OncologyVol. 16
Zhejiang Chinese Medical University (CN), Zhejiang Provincial Hospital of TCM (CN)
Good health and well-being
Openalex Percentile: Top 17%
Cancer Genomics and Diagnostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon